AACR Drug Discovery and Development (AACR D3)
July 21-24, 2026
Sheraton Boston Hotel
Boston, Massachusetts
Scientific Committee Cochairs
Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
This groundbreaking global conference will redefine the future of oncology drug development by challenging conventional paradigms and catalyzing innovation across disciplines. Bringing together a diverse and influential community—including leaders from biotech, pharma, academia, regulatory agencies, technology, venture capital, and patient advocacy—this conference is being launched to spark bold ideas and foster transformative collaborations.
Far beyond traditional didactic sessions, the conference will feature immersive and interactive formats to create dynamic networking opportunities and facilitate real-time problem-solving. Attendees will explore cutting-edge science, novel technologies, and emerging frameworks that promise to revolutionize how cancer therapies are discovered, developed, and delivered.
Objectives:
- Highlight emerging drug mechanisms and first-in-class targets
- Examine the impact of breakthroughs in cellular and molecular biology
- Showcase transformative tools, platforms, and AI-driven approaches in drug discovery
- Advance next-generation clinical trial designs and innovative endpoints
- Explore forward-thinking regulatory pathways to accelerate development timelines
- Foster strategic partnerships through curated networking experiences
- Facilitate networking and professional development opportunities to inspire and support oncology-focused entrepreneurs
Join us to shape the next era of oncology therapeutics.
